Compare Stocks: NBIX, TEVA, ONC, and RPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NBIX Neurocrine Biosciences	$138.35 -1.5%	$158.00	$122.14 ▼ $186.12	$14.06B	0.38	1.21 million shs	1.49 million shs
ONC BeOne Medicines	$365.27 -0.5%	$350.82	$253.95 ▼ $385.22	$40.10B	0.51	304,821 shs	372,395 shs
RPRX Royalty Pharma	$58.22 -0.3%	$59.59	$34.96 ▼ $64.38	$33.48B	0.44	3.44 million shs	2.84 million shs
TEVA Teva Pharmaceutical Industries	$39.84 +2.5%	$36.34	$18.83 ▼ $40.79	$46.43B	0.87	6.84 million shs	6.69 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NBIX Neurocrine Biosciences	+1.47%	-2.45%	-8.84%	-16.67%	-1.10%
ONC BeOne Medicines	+1.70%	+0.36%	+0.07%	+28.79%	+12.56%
RPRX Royalty Pharma	+0.27%	-0.12%	-4.08%	+4.10%	+66.58%
TEVA Teva Pharmaceutical Industries	-0.79%	-3.13%	+6.55%	+14.44%	+112.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NBIX Neurocrine Biosciences	$138.35 -1.5%	$158.00	$122.14 ▼ $186.12	$14.06B	0.38	1.21 million shs	1.49 million shs
ONC BeOne Medicines	$365.27 -0.5%	$350.82	$253.95 ▼ $385.22	$40.10B	0.51	304,821 shs	372,395 shs
RPRX Royalty Pharma	$58.22 -0.3%	$59.59	$34.96 ▼ $64.38	$33.48B	0.44	3.44 million shs	2.84 million shs
TEVA Teva Pharmaceutical Industries	$39.84 +2.5%	$36.34	$18.83 ▼ $40.79	$46.43B	0.87	6.84 million shs	6.69 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NBIX Neurocrine Biosciences	+1.47%	-2.45%	-8.84%	-16.67%	-1.10%
ONC BeOne Medicines	+1.70%	+0.36%	+0.07%	+28.79%	+12.56%
RPRX Royalty Pharma	+0.27%	-0.12%	-4.08%	+4.10%	+66.58%
TEVA Teva Pharmaceutical Industries	-0.79%	-3.13%	+6.55%	+14.44%	+112.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$202.73	46.53% Upside
ONC BeOne Medicines	3.06	Buy	$402.71	10.25% Upside
RPRX Royalty Pharma	3.00	Buy	$61.29	5.27% Upside
TEVA Teva Pharmaceutical Industries	2.92	Moderate Buy	$43.73	9.75% Upside

Current Analyst Ratings Breakdown

Latest NBIX, TEVA, ONC, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	NBIX Neurocrine Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$231.00 ➝ $214.00
9/23/2026	TEVA Teva Pharmaceutical Industries	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
9/22/2026	ONC BeOne Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C+)
9/16/2026	NBIX Neurocrine Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/14/2026	RPRX Royalty Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/11/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$182.00 ➝ $183.00
9/10/2026	ONC BeOne Medicines	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$407.00 ➝ $415.00
9/9/2026	TEVA Teva Pharmaceutical Industries	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/8/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
9/8/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/8/2026	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$198.00

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NBIX Neurocrine Biosciences	$2.86B	4.92	$5.01 per share	27.61	$32.63 per share	4.24
ONC BeOne Medicines	$5.34B	7.51	$3.96 per share	92.32	$39.77 per share	9.18
RPRX Royalty Pharma	$2.38B	14.08	$4.78 per share	12.19	$16.83 per share	3.46
TEVA Teva Pharmaceutical Industries	$17.26B	2.69	$3.79 per share	10.51	$6.88 per share	5.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NBIX Neurocrine Biosciences	$478.60M	$6.82	20.29	14.62	0.65	20.91%	22.43%	15.64%	10/27/2026 (Estimated)
ONC BeOne Medicines	$286.93M	$5.68	64.31	26.80	N/A	10.70%	14.23%	7.82%	N/A
RPRX Royalty Pharma	$770.95M	$1.45	40.15	10.53	1.37	32.14%	30.01%	14.91%	11/4/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	66.40	13.28	3.71	4.08%	32.64%	6.34%	11/3/2026 (Estimated)

Latest NBIX, TEVA, ONC, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/27/2026	Q3 2026	NBIX Neurocrine Biosciences	$2.59	N/A	N/A	N/A	$1.04 billion	N/A
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	$1.32	+$0.05	$0.04	$758.93 million	$674.14 million
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.61%	+24.01%	64.83%	5 Years
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest NBIX, TEVA, ONC, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.6%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NBIX Neurocrine Biosciences	N/A	1.87	1.75
ONC BeOne Medicines	0.17	3.40	3.06
RPRX Royalty Pharma	0.88	2.80	2.80
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NBIX Neurocrine Biosciences	92.59%
ONC BeOne Medicines	48.55%
RPRX Royalty Pharma	54.35%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
NBIX Neurocrine Biosciences	4.60%
ONC BeOne Medicines	6.19%
RPRX Royalty Pharma	18.84%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NBIX Neurocrine Biosciences	2,500	101.65 million	96.97 million	Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	N/A
RPRX Royalty Pharma	100	575.00 million	466.67 million	Optionable
TEVA Teva Pharmaceutical Industries	32,008	1.17 billion	1.16 billion	Optionable

NBIX, TEVA, ONC, and RPRX Headlines

Recent News About These Companies

Teva's Branded Drugs Take Center Stage in Its Growth Strategy

3 hours ago | finance.yahoo.com

Teva's Branded Drugs Take Center Stage in Its Growth Strategy

September 29 at 9:51 AM | zacks.com

More Industry Losses In Medicare Drug Prices Litigation

September 29 at 8:58 AM | healthaffairs.orgH

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

September 29 at 8:58 AM | fool.com

Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva

September 29 at 3:58 AM | rttnews.com

FDA approves Teva's Degevma as biosimilar to Xgeva

September 28 at 10:57 PM | streetinsider.com

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

September 28 at 5:57 PM | finance.yahoo.com

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

September 28 at 4:00 PM | globenewswire.com

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

September 28 at 12:55 PM | marketscreener.comM

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Short Interest Update

September 24, 2026 | marketbeat.com

Roberto Mignone Sells 367,600 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

September 24, 2026 | americanbankingnews.com

Teva Pharmaceutical Industries stock trades 4.36 percent below its yearly high

September 23, 2026 | ad-hoc-news.deA

Forge’s Fierce Pharma Week Delivered a Powerhouse Event with Over 3,500 Pharmaceutical and Biotech Decision-Makers and Innovators, Representing a 21% Increase in Attendees ...

September 23, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Ltd: Teva Releases Q3 2026 Aide Memoire

September 23, 2026 | finanznachrichten.de

Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

September 23, 2026 | finanznachrichten.de

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

September 23, 2026 | finance.yahoo.com

Teva Releases Q3 2026 Aide Memoire

September 23, 2026 | finance.yahoo.com

Teva Releases Q3 2026 Aide Memoire

September 23, 2026 | financialpost.comF

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

September 23, 2026 | financialpost.comF

Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026

September 23, 2026 | quiverquant.comQ

Teva Releases Q3 2026 Aide Memoire

September 23, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NBIX, TEVA, ONC, and RPRX Company Descriptions

Neurocrine Biosciences NASDAQ:NBIX

$138.35 -2.09 (-1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$139.03 +0.68 (+0.49%)

As of 05:24 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

BeOne Medicines NASDAQ:ONC

$365.27 -1.73 (-0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$364.86 -0.41 (-0.11%)

As of 05:29 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Royalty Pharma NASDAQ:RPRX

$58.22 -0.15 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$58.98 +0.77 (+1.31%)

As of 05:21 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$39.84 +0.96 (+2.47%)

Closing price 03:59 PM Eastern

Extended Trading

$39.97 +0.13 (+0.33%)

As of 05:29 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBIX, TEVA, ONC, and RPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBIX, TEVA, ONC, and RPRX Earnings

Compare Dividends

Latest NBIX, TEVA, ONC, and RPRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBIX, TEVA, ONC, and RPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NBIX, TEVA, ONC, and RPRX Company Descriptions

Neurocrine Biosciences NASDAQ:NBIX

BeOne Medicines NASDAQ:ONC

Royalty Pharma NASDAQ:RPRX

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools